Iambic Therapeutics Inc(IAM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
IAM
New Iambic Therapeutics Inc
$14.26
-0.41 ▼ -2.79%
Oct 23 at 7:47 PM ET (Korea 10/24 08:47)$14.34
+0.08 ▲ +0.56%
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 28.78% | Shs Outstand | 47.4M | Perf Week | -40.11% |
| Market Cap | 0.68B | Forward P/E | - | EPS next Y | - | Insider Trans | 6.54% | Shs Float | 33.8M | Perf Month | - |
| Enterprise Value | - | PEG | - | EPS next Q | - | Inst Own | - | Short Float | - | Perf Quarter | - |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | - | Perf Half Y | - |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | - | Perf YTD | -11.7% |
| Book/sh | - | P/C | - | EPS past 3/5Y | - | ROE | - | 52W High | -42.96% ($25.00) | Perf Year | - |
| Cash/sh | - | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 1.13% ($14.10) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 20.46% - | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 3.84 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | - | EPS Q/Q | - | Profit Margin | - | RSI (14) | - | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | - | Sales Q/Q | - | SMA20 | -16.68% ($17.11) | Beta | - | Target Price | - |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -16.68% ($17.11) | Rel Volume | 0.39 | Prev Close | $14.67 |
| Employees | - | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -16.68% ($17.11) | Avg Volume(3M) | 1.55M | Price | $14.26 |
| IPO | 2026/10/15 | Option/Short | No/Yes | Trades | 3561 | Volume | 610,380 | Change | -2.79% |
Company
Iambic Therapeutics IncIAM | NASD | Biotechnology 🧬 자체 인공지능과 자동화된 화학·생물학 실험을 결합해 신약을 발굴하는 미국 임상 단계 바이오테크 기업입니다. 후보물질 발굴부터 임상 개발 가능성 판단까지를 한 플랫폼으로 묶고, 자체 신약 개발과 대형 제약사·기술 기업과의 공동 연구 계약을 함께 운영합니다.
Quote
Over the past 1 year, on the lower side
43% below its 1-year high.
Now $14.26
52w low$14.1052w high$25.00
52W Range1%
Volume 610,380
Traded less than usual. That is 39% of its average volume.
Has it trended upward long-term? B
Long-term returns are roughly flat
Tap to view numbers
How about dividends?
No dividend
There is no profit to distribute yet.
Who owns it? B
Ownership is about average
Shareholder Composition Guide
Tap to view numbers
Peer comparison Biotechnology
It ranks #183 of 595 in the industry
Based on market cap of $676M.
OABI#182 OmniAb Inc $678M PER - IAM#183 Iambic Therapeutics Inc $676M PER - 
IMMX#184 Immix Biopharma Inc $676M PER - 
SGMT#185 Sagimet Biosciences Inc $674M PER - 
DNA#186 Ginkgo Bioworks Holdings Inc $673M PER - Reads on this stock 1 posts
FAQ
FAQ
What kind of company is IAM?
IAM belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IAM?
The market cap of IAM is approximately $676M, ranking 2,890 within its sector.
What is the 52-week high and low for IAM?
IAM has recorded a 52-week high of $25.00 and a low of $14.10.
Briefs · earnings · signals, first Telegram · KakaoTalk channels
